Research paper
Treatment of pediatric epilepsy
Broad 2026 review of pediatric epilepsy treatment covering ASMs, dietary therapy, immunotherapy, surgery, and neuromodulation. Consolidates current standard-of-care across pediatric epilepsy syndromes.
Li X, et al.
Markdown path
content/research/papers/2026-li-pediatric-epilepsy-treatment-review.mdFindings
Broad 2026 review of pediatric epilepsy treatment covering ASMs, dietary therapy, immunotherapy, surgery, and neuromodulation. Consolidates current standard-of-care across pediatric epilepsy syndromes.
Why it may matter for Levi
Useful as a reference-level update but does not add specific Levi-relevant claims beyond what is already in the corpus. Low-urgency full-text review.
Li et al. (2026) — Comprehensive pediatric epilepsy treatment review
Source
- Pediatric Discovery, 2026.
Why in corpus
Broad 2026 review of the pediatric epilepsy treatment landscape, including emerging gene therapy (ASOs, AAV, CRISPR) and dietary therapy as adjuncts.
Key findings
- Reviews the standard and emerging treatment landscape across pediatric epilepsies.
- Highlights gene therapy approaches as an emerging frontier: antisense oligonucleotides (ASOs), adeno-associated virus (AAV) vectors, CRISPR-based gene editing.
- Ketogenic diet positioned as an important adjunctive therapy for drug-resistant epilepsy syndromes including DEE-SWAS.
Levi-relevant takeaways
- Gene therapy is not a near-term option for Levi absent a confirmed targetable genetic diagnosis. Relevant long-horizon if the mosaic-sensitive or episignature workups identify a specific target.
- Reinforces ketogenic diet as a contingent option (complements Figueroa 2026 and Qiao 2024 already in the corpus).
- Worth tracking as the ASO / AAV landscape for specific epilepsy genes (SCN1A, SCN2A, SCN8A, STXBP1, KCNQ2, KCNT1, etc.) matures — if Levi ever gets a specific genetic diagnosis, gene therapy status for that gene will be immediately relevant.